Comparison 4.

Danoprevir versus placebo/no intervention

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Hepatitis C‐related morbidity or all‐cause mortality	9	781	Odds Ratio (M‐H, Fixed, 95% CI)	0.56 [0.06, 5.19]
2 Hepatitis C‐related morbidity or all‐cause mortality ‐ according to dose	9	781	Odds Ratio (M‐H, Fixed, 95% CI)	0.56 [0.06, 5.19]
2.1 Over or equal to median dose	6	606	Odds Ratio (M‐H, Fixed, 95% CI)	0.56 [0.06, 5.19]
2.2 Under median dose	3	175	Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 Not available	0	0	Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Serious adverse events	9		Odds Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 Serious adverse events ‐ according to median dose	9		Odds Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4.1 Over or equal to median dose	6		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 Under median dose	3		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.3 Not available	0		Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Without sustained virological response	5	642	Odds Ratio (M‐H, Fixed, 95% CI)	0.19 [0.12, 0.32]
6 Without sustained virological response ‐ according to median dose	5	642	Odds Ratio (M‐H, Fixed, 95% CI)	0.19 [0.12, 0.32]
6.1 Over or equal to median dose	4	537	Odds Ratio (M‐H, Fixed, 95% CI)	0.18 [0.11, 0.32]
6.2 Under median dose	1	105	Odds Ratio (M‐H, Fixed, 95% CI)	0.27 [0.07, 0.99]
6.3 Not available	0	0	Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]